Earnings Review
Glenmark Pharma PAT jumps manifold Q4 despite one-time cost
This story was originally published at 22:25 IST on 29 May 2026
Register to read our real-time news.Informist, Friday, May 29, 2026
Please click here to read all liners published on this story
--Glenmark Pharma Jan-Mar consol PAT INR 3.01 bln vs INR 46.50 mln yr ago
--Glenmark Pharma Jan-Mar consol revenue INR 37.71 bln vs INR 32.56 bln yr ago
--Glenmark Pharma Jan-Mar net profit includes one-time cost INR 3.73 bln
--Glenmark Pharma Jan-Mar profit excluding exceptional cost INR 6.75 bln
--Glenmark Pharma to pay INR 2.5 per share dividend
--Glenmark Pharma FY26 consol net profit INR 13.62 bln vs INR 10.47 bln yr ago
--Glenmark Pharma FY26 consol revenue INR 169.83 bln vs INR 133.22 bln year ago
By Gunjan Rajput
NEW DELHI – Glenmark Pharmaceuticals Ltd.'s net profit during the March quarter surged 65 times on year, driven by strong revenue growth and a low base of last year. However, the earnings were affected by an exceptional charge.
The drugmaker's consolidated net profit surged to INR 3.01 billion in the March quarter from INR 46.5 million a year ago. However, the net profit fell short of analysts' expectations of INR 4.16 billion-INR 5.98 billion.
The company reported a sharp jump in net profit due to a low base of last year, when the company had reported a one-time cost of INR 3.7 billion. The company also reported a one-time cost of INR 3.7 billion in the latest quarter but the impact of somewhat offset by higher revenues. Excluding this cost, net profit was INR 6.75 billion, exceeding the Street's estimates.
The company's consolidated revenue from operations increased 15.8% on year to INR 37.71 billion from INR 32.56 billion a year ago. This was inline with expectations of INR 37 billion-INR 38 billion revenue.
The company's total expenses rose nearly 11% on year to INR 32 billion from INR 28.87 billion from a year ago. Other expenses, which account for nearly 30% of the total expenses, rose over 9% on year to INR 9.48 billion. Employee costs rose over 20% on year to INR 8.87 billion. Expenses related to purchase of stock-in-trade rose nearly 30% on year to INR 4.46 billion and cost of raw materials consumed declined 8% on year to INR 7.31 billion.
Glenmark Pharmaceuticals has approved the transfer of the nebulizer brands portfolio to Glenmark Healthcare Ltd. and the transaction is expected to be completed by Jun. 30. The transfer is expected to be carried out at a cash consideration of INR 2.23 billion, as per an exchange filing.
For the financial year 2025-26 (Apr-Mar), Glenmark reported a consolidated net profit rose over 30% on year to INR 13.62 billion compared with INR 10.47 billion in the previous year, while revenue rose over 27% on year to INR 169.83 billion from INR 133.22 billion. The board recommended a dividend of INR 2.5 per equity share. Friday, shares of the company closed at INR 2,274.90 on the National Stock Exchange, down 4.6% from Wednesday. Equity markets were shut Thursday on account of Id-ul-Zuha. End
Edited by Depshikha Bhardwaj
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (11) 4220-1000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
